Programs & Expertise
LinusBio Precision Exposome Medicine Program Follows The Evolving Precision Medicine Paradigm
LinusBio is developing and commercializing hair strand tests for complex health conditions.
A substantial need exists for new biomarkers, especially for CNS conditions and GI disorders caused by the interplay of genetics and the environment. Extensive research in these areas has yet to result in genetic tests to guide diagnosis and treatment choices. Without biological tests, doctors continue to rely on questionnaires and specialists’ observations of symptoms for their clinical decision-making.
Our goal is to bring precision exposome medicine to patients with autism, ADHD, schizophrenia, ALS, irritable bowel syndrome, and other complex conditions lacking biomarkers with evidence of clinical utility.
Imagine if a lab test:
- could reveal that a preschool child has ADHD and reveal which treatment would give them the best results with the fewest adverse effects
- could reveal that a person is in the very early stages of ALS so they can begin treatment when medicines might be most effective
- could spare a person with irritable bowel syndrome from an invasive diagnostic odyssey.
We are working to make this vision a reality. Temporal exposomic sequencing has the potential to transform how complex disorders are diagnosed and treated. Our tests might identify conditions before symptoms appear, aid in diagnosing and monitoring the progression of health conditions, serve as objective molecular endpoints in clinical trials, characterize the response to treatment, and more.
| Disorder Type | Disorder | Patent & PCT Submitted | Clinical & Epid. Studies | Pathway Characterization | Current Status |
|---|---|---|---|---|---|
| CNS | 1001 – Early Autism Detection | FDA Breakthrough Designation granted | |||
| CNS | 1002 – Attention Deficit Hyperactive Disorder | Enrollment ongoing | |||
| CNS | 1003 — Psychosis & schizophrenia | Enrollment ongoing | |||
| CNS | 1004 – Lou Gehrig’s Disease | FDA submission Q2 2022 | |||
| Gut | IBS, Eosinophilic Esophagitis, Microbiome | Enrollment ongoing | |||
| Cancer | Pediatric Cancer | Enrollment ongoing | |||
| Data Science | Global biodynamics dataset | Prototype complete |
Expertise
LinusBio Precision Exposome Medicine Program Follows The Evolving Precision Medicine Paradigm:
- Patient group stratification, disease & patient phenotyping
- Biomarker & diagnostics, patient-journey monitoring
- Characterization of pathways and biological mechanisms for target discovery
- Drug development and clinical-trial design
Near-Future Deliverables For Neurodevelopmental Disease:
- First-in-class StrandDx™-ASD biomarker & diagnostic for autism.
- FDA Breakthrough Designation for ASD, awarded.
- Market access & reimbursement program for deNovo in vitro diagnostic.
Milestone Collaborations Achieved On Two Fronts:
- ASD pharmaceutical / clinical trials for older ASD patients
- Non-pharmaceutical / nutraceuticals for high-risk ASD infants
Next Breakthrough Programs:
- Amyotrophic lateral sclerosis (ALS)
- Inflammatory bowel disease (IBD)
- Attention deficit hyperactive disorder (ADHD)
- Psychosis/schizophrenia
- Renal disease
- Pediatric cancer
